GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Instituto Rosenbusch SA (BUE:ROSE) » Definitions » EV-to-Revenue
中文

Instituto Rosenbusch (BUE:ROSE) EV-to-Revenue

: 1.00 (As of Today)
View and export this data going back to . Start your Free Trial

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Instituto Rosenbusch's enterprise value is ARS4,540 Mil. Instituto Rosenbusch's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was ARS4,528 Mil. Therefore, Instituto Rosenbusch's EV-to-Revenue for today is 1.00.

The historical rank and industry rank for Instituto Rosenbusch's EV-to-Revenue or its related term are showing as below:

BUE:ROSE' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.3   Med: 1.16   Max: 2.49
Current: 1

During the past 13 years, the highest EV-to-Revenue of Instituto Rosenbusch was 2.49. The lowest was 0.30. And the median was 1.16.

BUE:ROSE's EV-to-Revenue is ranked better than
79.04% of 1026 companies
in the Drug Manufacturers industry
Industry Median: 2.28 vs BUE:ROSE: 1.00

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-24), Instituto Rosenbusch's stock price is ARS91.50. Instituto Rosenbusch's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was ARS106.32. Therefore, Instituto Rosenbusch's PS Ratio for today is 0.86.


Instituto Rosenbusch EV-to-Revenue Historical Data

The historical data trend for Instituto Rosenbusch's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Instituto Rosenbusch Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.87 1.02 0.51 0.33 0.78

Instituto Rosenbusch Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.33 0.30 0.39 0.50 0.78

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Instituto Rosenbusch's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Instituto Rosenbusch EV-to-Revenue Distribution

For the Drug Manufacturers industry and Healthcare sector, Instituto Rosenbusch's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Instituto Rosenbusch's EV-to-Revenue falls into.



Instituto Rosenbusch EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Instituto Rosenbusch's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=4540.001/4528.056
=1.00

Instituto Rosenbusch's current Enterprise Value is ARS4,540 Mil.
Instituto Rosenbusch's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS4,528 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Instituto Rosenbusch  (BUE:ROSE) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Instituto Rosenbusch's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=91.50/106.32
=0.86

Instituto Rosenbusch's share price for today is ARS91.50.
Instituto Rosenbusch's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS106.32.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Instituto Rosenbusch EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Instituto Rosenbusch's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Instituto Rosenbusch (BUE:ROSE) Business Description

Traded in Other Exchanges
N/A
Address
Hipolito Yrigoyen 1628, Buenos Aires, ARG, C1089AAF
Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.